secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001171843-26-001838
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus reports FY2025 results; Moderna settlement $950M; two more imdusiran functional cures
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $91.5M at Dec 31, 2025 vs $122.6M at Dec 31, 2024.
- Net loss $33.5M for 2025 vs $69.9M in 2024; revenue $14.1M, up from $6.2M.
- Moderna settlement: $950M noncontingent due July 2026; contingent $1.3B on 1498 ruling. Arbutus gets 20% of noncontingent after costs.
- Two additional imdusiran Phase 2a patients achieved functional cure for chronic HBV, total 10 to date.
- Company evaluating return of capital to shareholders in Q3 2026 after Moderna payment receipt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326001838/0001171843-26-001838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326001838/f8k_032026.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-001838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer